Janssen-Cilag International, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency. The submission is seeking approval for an indication extension of Darzalex subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson says Rybrevant-chemotherapy combo approved by FDA
- Legend Biotech gets CHMP recommendation for expansion of Carvykti label
- BTIG medical technology analyst to hold analyst/industry conference call
- Johnson & Johnson: FDA approves sBLA for TECVAYLI for reduced dosing frequency
- Genmab price target lowered to $50 from $54 at Truist
